drugset / Trial / NCT00495365
A Dose Conversion Study of Epoetin Alfa in Subjects With the Anemia of Chronic Kidney Disease.
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study was to evaluate hemoglobin stability in subjects who had received darbepoetin alfa for a minimum of 3 months prior to study entry who were then converted to epoetin alfa at the same dosing frequency to maintain a hemoglobin level of 12 plus or minus 1 g/dL (range 11-13- g/dL).
Timeline
- Start
- 2003-06
- Primary completion
- —
- Completion
- 2003-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | epoetin alfa | Protein / enzyme biologic | 20000 iu | Subcutaneous |
| Subject | epoetin alfa | Protein / enzyme biologic | 30000 iu | Subcutaneous |
| Subject | epoetin alfa | Protein / enzyme biologic | 40000 iu | Subcutaneous |